Market Overreaction Creates Compelling Entry Point for Ultragenyx (RARE)

A note on RBCCM's update

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

This post is an update on my original post from June 25th and analyzes a recent RBC note that provides an upside scenario price target of $89. In my opinion, I agree with RBC’s assessment: The market is mispricing this for those that have duration.